Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.
about
Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design
P2860
Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@ast
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@en
type
label
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@ast
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@en
prefLabel
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@ast
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@en
P2093
P2860
P356
P1476
Apolipoprotein B100 is require ...... pomersen inhibits hepatitis C.
@en
P2093
Andrew Yang
Christina Mark
Clary B Clish
Cynthia Brisac
Dahlene Fusco
Daniel L Motola
Esperance A K Schaefer
James Meixiong
Lee F Peng
P2860
P304
P356
10.3748/WJG.V22.I45.9954
P407
P577
2016-12-01T00:00:00Z